COMMUNIQUÉS West-GlobeNewswire

-
Maple Leaf Green World Inc. Signs A Letter Of Intent To Supply Hemp Seeds To A South East Asian CBD Producer
17/09/2019 -
Optinose Announces Departure of Chief Commercial Officer
17/09/2019 -
Translate Bio Announces Proposed Public Offering of Common Stock
17/09/2019 -
Devonian annonce la prolongation de son placement privé
17/09/2019 -
Theresa McConeghey Receives NADP Gabryl Award
17/09/2019 -
Spineway : Adjournment of the Ordinary and Extraordinary General Shareholders’ Meeting to be held on 19 september 2019
17/09/2019 -
SPINEWAY : Ajournement de l'Assemblée Générale Mixte du 19 septembre 2019
17/09/2019 -
Michael Cole Receives NADP Don Mayes Leadership Award
17/09/2019 -
Veyonda® and Radiotherapy Profiled at Key Oncology Meeting
17/09/2019 -
Ear, Nose & Throat Associates Welcomes Dr. Leanna-Marie Robertson
17/09/2019 -
Pressure BioSciences Prepares for Growth, Adding Daniel J. Shea as Chief Financial Officer
17/09/2019 -
Beroni USA is Ready to Commercialise a Diagnostic Kit for Detecting Zika, Dengue, Chikungunya and West Nile Viruses Worldwide
17/09/2019 -
INmune Bio Invited to Speak on Company’s Advancements in Cancer Treatments at the Targeting Innate Immunity Congress and MarketsandMarkets Next Gen Immuno-Oncology Congress
17/09/2019 -
Leanne Ebert Murphy Joins Comprehensive Pharmacy Services as Executive Vice President and General Counsel
17/09/2019 -
InnovaHealth Partners Invests in Koelis, a Leader in Prostate Cancer Diagnostics and Treatment
17/09/2019 -
Les partenaires d'InnovaHealth investissent dans Koelis, un leader du diagnostic et du traitement du cancer de la prostate
17/09/2019 -
Rafael Pharmaceuticals Announces Expansion into France of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for Patients with Metastatic Pancreatic Cancer
17/09/2019 -
The Delta Companies Named One of the Largest Staffing Firms in the U.S. by SIA
17/09/2019 -
Generex Biotechnology Announces First Patient Enrolled in the Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (Keytruda®) for the Treatment of Triple Negative Breast Cancer
17/09/2019
Pages